Worth reading
83Important
Scored from 4 of 5 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ended June 2024 · Full yearNet Sales—→6,820million
—
Operating profit—→280million
—
Ordinary income—→280million
—
Profit attributable to owners of the parent—→180million
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
化粧品事業では顧客の在庫調整が次期上期まで継続する見込み。ヘルスケアサポート事業では契約健康保険組合数の増加、健康補助食品事業では積極的な広告宣伝活動と新商品投入、その他の事業では受注残高や主力商品の販売減少傾向を見込んでいる。
Details and amount of extraordinary loss
固定資産除却損1百万円（連結損益計算書では1,887千円）
Previous-period results売上高8,079百万円、営業利益725百万円、経常利益727百万円、親会社株主に帰属する当期純利益451百万円
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥6,820 million |
| Operating profit | Not disclosed → ¥280 million |
| Ordinary income | Not disclosed → ¥280 million |
| Profit attributable to owners of the parent | Not disclosed → ¥180 million |
| Fiscal Period Covered | Fiscal year ended June 2024 |
| Period Covered | Full year |
| Previous-period results | 売上高8,079百万円、営業利益725百万円、経常利益727百万円、親会社株主に帰属する当期純利益451百万円 |
| Reason for the revision | 化粧品事業では顧客の在庫調整が次期上期まで継続する見込み。ヘルスケアサポート事業では契約健康保険組合数の増加、健康補助食品事業では積極的な広告宣伝活動と新商品投入、その他の事業では受注残高や主力商品の販売減少傾向を見込んでいる。 |
| Details and amount of extraordinary loss | 固定資産除却損1百万円（連結損益計算書では1,887千円） |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
Net income per sharePublication date of previous forecastDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.2023年6月期は、化粧品事業で中国市場向け商品の競争激化、健康補助食品事業で広告効率の悪化や新規顧客獲得数の減少、機能性素材開発事業でラクトフェリン原料の販売数量の伸び悩みなどがあった。2024年6月期は、化粧品事業で顧客の在庫調整が次期上期まで続く見込みである一方、ヘルスケアサポート事業の契約健康保険組合数の増加や、健康補助食品事業の広告宣伝・新商品投入を見込んでいる。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.